<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603041</url>
  </required_header>
  <id_info>
    <org_study_id>UArkansasFayetteville</org_study_id>
    <nct_id>NCT03603041</nct_id>
  </id_info>
  <brief_title>Nutrition, Body Composition, and Sleep</brief_title>
  <acronym>SHAPE</acronym>
  <official_title>The Effect of Protein and Omega-3 Fatty Acid Supplementation on Body Composition, Sleep, Cardiometabolic Health and Strength in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas, Fayetteville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas, Fayetteville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to determine if protein and omega-3 fatty acid supplementation
      improve sleep, improve body composition, and improve markers of metabolic health in
      postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>Change in sleep quality from baseline (day 0) to 16 weeks.</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) will assess sleep quality and disturbance. This is a elf-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven &quot;component&quot; scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Change in dietary intake from baseline (day 0) to 16 weeks.</time_frame>
    <description>Dietary intake will be measured using 3-day, weighed food records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quantity</measure>
    <time_frame>Change in sleep quantity from baseline (day 0) to 16 weeks.</time_frame>
    <description>Sleep duration will be measured using Actigraph monitors worn on the wrist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Body composition will be measured using dual x-ray absorptiometry (DEXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure (REE)</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>REE will be measured using indirect calorimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orexin</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Intravenous blood samples will be collected and orexin measured using a commercial kit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mood</measure>
    <time_frame>Change in sleep quality from baseline (day 0) to 16 weeks.</time_frame>
    <description>Mood will be assessed using the Profile of Mood States (POMS) questionnaire. The POMS measures six different dimensions of mood swings over a period of time. These include: Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment. A five-point scale ranging from &quot;not at all&quot; to &quot;extremely&quot; is used to assess participant mood states.</description>
  </other_outcome>
  <other_outcome>
    <measure>Strength</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Strength will be assessed using a standard hand-grip dynamometer .</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Intravenous blood samples will be collected and glucose measured using a commercial kit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Intravenous blood samples will be collected and insulin measured using a commercial kit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipids</measure>
    <time_frame>On day 1 and day 112 (final day of 16-week intervention) of study.</time_frame>
    <description>Intravenous blood samples will be collected and blood lipids measured using a commercial kit.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sleep</condition>
  <condition>Body Composition</condition>
  <condition>Strength</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Energy Expenditure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These participants will maintain their daily food and exercise routine and will receive no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey Protein Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive protein supplementation daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acids (O3FA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive O3FA supplementation daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey Protein and O3FA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive protein and O3FA supplementation daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey Protein and Placebo Fat Source</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive protein and placebo fat source supplementation daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein</intervention_name>
    <description>Participants in the protein arms will receive whey protein daily for 16 weeks.</description>
    <arm_group_label>Whey Protein Supplementation</arm_group_label>
    <arm_group_label>Whey Protein and O3FA</arm_group_label>
    <arm_group_label>Whey Protein and Placebo Fat Source</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.</description>
    <arm_group_label>Omega-3 Fatty Acids (O3FA)</arm_group_label>
    <arm_group_label>Whey Protein and O3FA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Postmenopausal women (12+ months following last reported menstrual cycle)

        Exclusion Criteria:

          -  food allergies

          -  diet restrictions

          -  do not habitually eat breakfast

          -  picky eaters\regularly consume protein or omega-3 related supplements

          -  consume omega-3 fatty acid rich fish (tuna, salmon, etc.) greater than two times per
             month -have any other diet-related conditions that would prevent them from consuming
             whey protein supplements and/or omega-3 fatty acid supplements

          -  smoking

          -  habitual alcohol consumption (&gt; 4 drinks/week)

          -  medication impacting appetite or metabolism

          -  Lipid or blood pressure lowering medication

          -  Hormone replacement therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie I Baum, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie I Baum, PhD</last_name>
    <phone>479-575-4474</phone>
    <email>baum@uark.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie I Baum, PhD</last_name>
      <phone>479-575-4474</phone>
      <email>baum@uark.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>January 25, 2020</last_update_submitted>
  <last_update_submitted_qc>January 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arkansas, Fayetteville</investigator_affiliation>
    <investigator_full_name>Jamie Baum</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

